etoposide has been researched along with Hearing Loss in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, H; Koo, HH; Lee, JW; Lim, DH; Ma, Y; Shin, HJ; Suh, YL; Sung, KW; Yoo, KH | 1 |
| Ash, S; Cohen, IJ; Issakov, J; Kollender, Y; Shkalim-Zemer, V; Toledano, H; Yaniv, I | 1 |
| Bremnes, RM; Brydøy, M; Fosså, SD; Gundersen, POM; Haugnes, HS; Hjelle, LV; Oldenburg, J; Sprauten, M; Tandstad, T; Wilsgaard, T | 1 |
| Bunne, M; Fosså, SD; Gundersen, POM; Osnes, T; Skalleberg, J; Småstuen, MC; Solheim, O | 1 |
| Abu Zaid, M; Althouse, S; Ardeshir-Rouhani-Fard, S; Beard, CJ; Cook, R; Einhorn, LH; Feldman, DR; Fossa, SD; Fung, C; Hamilton, RJ; Kerns, SL; Kollmannsberger, CK; Lipshultz, SE; Monahan, P; Sesso, HD; Travis, LB; Vaughn, DJ; Williams, AM | 1 |
| Armstrong, G; Chester, J; Joffe, J; Mazhar, D; Parashar, D; Powles, T; Rimmer, Y; Shamash, J; Stark, D; Wason, J; White, J; Williams, MV | 1 |
| Dubs, A; Honegger, H; Jacky, E; Stahel, R; Taverna, C | 1 |
| Beaudoin, A; De Gramont, A; El Mesbahi, O; Louvet, C | 1 |
| Budnick, A; Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Arakawa, H; Baba, H; Egami, H; Futamura, M; Ichikawa, H; Kamino, H; Kitamura, N; Kiyono, T; Masuda, Y; Miyamoto, Y; Nakamura, Y; Ohki, M; Ohnishi, S; Ohta, T | 1 |
| Lambert, MP; Meadows, AT; Shields, C | 1 |
| Ahn, DC; Doroshow, JH; Forman, SJ; Hwang, L; Leong, LA; Lev-Ran, A; Margolin, KA; Morgan, RJ; Raschko, JW; Somlo, G | 1 |
| Cabanillas, F; Dicke, KA; Hagemeister, F; Horwitz, LJ; Jagannath, S; Spinolo, JA; Spitzer, G; Velásquez, W | 1 |
| Abe, H; Ikeda, J; Ishii, N; Kato, T; Sawamura, Y; Shirato, H; Tada, M | 1 |
| Benesch, M; Kerbl, R; Lackner, H; Oberbauer, R; Pakisch, B; Schwinger, W; Urban, C | 1 |
| Breatnach, F; Hartmann, O; Philip, T; Pinkerton, CR; Zucker, JM | 1 |
5 trial(s) available for etoposide and Hearing Loss
| Article | Year |
|---|---|
Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hearing Loss; Humans; Lung Diseases; Male; Neoplasms, Germ Cell and Embryonal; Polyethylene Glycols; Prognosis; Recombinant Proteins | 2011 |
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Topics: Antineoplastic Agents; Child, Preschool; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Hearing Loss; Humans; Male; Neuroblastoma | 2006 |
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Creatinine; Cyclophosphamide; Dopamine; Double-Blind Method; Electrolytes; Epidermal Growth Factor; Etoposide; Female; Hearing Loss; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Sarcoma; Soft Tissue Neoplasms; Water-Electrolyte Imbalance | 1995 |
Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hearing Loss; Hodgkin Disease; Humans; Kidney Diseases; Male; Middle Aged; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome | 1993 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Deafness; Disease Progression; Disease-Free Survival; Etoposide; Follow-Up Studies; Glioma; Hearing Loss; Hematologic Diseases; Humans; Ifosfamide; Infections; Life Tables; Lomustine; Medulloblastoma; Methotrexate; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Vincristine | 1998 |
11 other study(ies) available for etoposide and Hearing Loss
| Article | Year |
|---|---|
Tandem High-dose Chemotherapy without Craniospinal Irradiation in Treatment of Non-metastatic Malignant Brain Tumors in Very Young Children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child, Preschool; Craniospinal Irradiation; Etoposide; Female; Hearing Loss; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Male; Neoplasm Recurrence, Local; Progression-Free Survival; Risk Factors; Salvage Therapy; Survival Rate; Thiotepa; Transplantation, Autologous | 2020 |
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Substitution; Etoposide; Female; Follow-Up Studies; Hearing Loss; Humans; Ifosfamide; Kidney Diseases; Leucovorin; Male; Methotrexate; Osteosarcoma; Pilot Projects; Stroke Volume; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cancer Survivors; Carboplatin; Cardiovascular Diseases; Cisplatin; Combined Modality Therapy; Comorbidity; Etoposide; Follow-Up Studies; Hearing Loss; Humans; Hypogonadism; Luteinizing Hormone; Male; Middle Aged; Norway; Orchiectomy; Peripheral Nervous System Diseases; Surveys and Questionnaires; Testicular Neoplasms; Tinnitus; Vinblastine; Young Adult | 2016 |
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Bleomycin; Case-Control Studies; Chemotherapy, Adjuvant; Child; Cisplatin; Etoposide; Female; Hearing Loss; Humans; Longitudinal Studies; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Ovariectomy; Platinum; Vinblastine; Young Adult | 2017 |
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Canada; Case-Control Studies; Cisplatin; Etoposide; Exercise; Health Status; Hearing Loss; Humans; Long Term Adverse Effects; Male; Middle Aged; Obesity; Peripheral Nervous System Diseases; Prevalence; Protective Factors; Raynaud Disease; Risk Factors; Smoking; Surveys and Questionnaires; Survivors; Testicular Neoplasms; Tinnitus; United States; Young Adult | 2017 |
Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Germinoma; Hearing Loss; Humans | 2004 |
[Tumor lysis syndrome after chemotherapy for colon small cell carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Etoposide; Female; Hearing Loss; Humans; Liver Neoplasms; Middle Aged; Postoperative Care; Tumor Lysis Syndrome | 2004 |
The potential role of DFNA5, a hearing impairment gene, in p53-mediated cellular response to DNA damage.
Topics: Animals; Apoptosis; Base Sequence; Binding Sites; Chlorocebus aethiops; COS Cells; DNA Damage; Etoposide; Exons; Gene Expression Regulation, Neoplastic; Genome, Human; Hearing Loss; Humans; Mice; Microarray Analysis; Molecular Sequence Data; Protein Transport; Receptors, Estrogen; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2006 |
A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Evoked Potentials, Auditory, Brain Stem; Hearing; Hearing Loss; Humans; Infant; Infant, Newborn; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Vincristine | 2008 |
Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Hearing Loss; Humans; Ifosfamide; Infant; Magnetic Resonance Imaging; Male; Medulloblastoma; Neuroectodermal Tumors, Primitive; Pilot Projects; Radiotherapy, Adjuvant; Remission Induction; Skull Base Neoplasms | 1996 |
Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Etoposide; Hearing Loss; Humans; Infant; Neuroblastoma; Neutropenia; Pilot Projects; Water-Electrolyte Imbalance | 1988 |